Black women experienced higher rates of breast cancer-related lymphedema than white women, and Black race was the strongest predictor of lymphedema development, according to results presented at the San Antonio Breast Cancer Symposium.
Results from the registration-enabling EXPLORER and PATHFINDER trials of Ayvakit (avapritinib) highlighted its robust efficacy and safety datasets in advanced systemic mastocytosis.
Yale Cancer Center researchers have revealed the structure of anaplastic lymphoma kinase—a molecule that drives several cancers, including pediatric neuroblastoma, B-cell lymphomas, and myofibroblast tumors—opening new paths for cancer treatment.
IMGN853 (mirvetuximab soravtansine) yielded positive top-line data in the pivotal phase III SORAYA trial evaluating the safety and efficacy of the monotherapy in patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer who have been previously treated with Avastin (bevacizumab).
Suzanne M. Miller, a professor in the Cancer Prevention and Control Program at Fox Chase Cancer Center, developed a special edition of Translational Behavioral Medicine that summarizes several major lines of cancer prevention and control research and outlines future directions.
The American Lung Association’s 4th annual “State of Lung Cancer” report showed that the lung cancer five-year survival rate increased 14.5% nationally to 23.7% yet remains significantly lower among communities of color.
According to the DREAMseq phase III clinical trial, the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) (N/I), followed by the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) (D/T) if there was disease progression, led to a significant improvement in estimated 2-year overall survival from the start of treatment (72%) when compared to the opposite treatment sequence (52%).
According to a study led by University of Michigan researchers, fewer than one-third of hospitals had immediate availability of all-trans retinoic acid (ATRA), which is initiated early in the treatment of acute promyelocytic leukemia to prevent major bleeding, clotting, and potential death.
In findings led by researchers at Yale Cancer Center and collaborating institutions, the monoclonal antibody drug sotigalimab, combined with Bristol Myers Squibb’s immunotherapy drug Opdivo (nivolumab), resulted in tumor shrinkage in patients with advanced melanoma whose tumors had progressed on prior immunotherapy.
A study led by Yale Cancer Center found that more men received a prostate-specific antigen (PSA) test to detect prostate cancer following revisions to the recommendation by the U.S. Preventative Services Task Force on screening.
